Carmelo Raffo

Dr. Carmelo Raffo

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2024 in Circulation
Verified
Journal Article
Open access
DGDaniele Giacoppo
Daniele Giacoppo
CLClaudio Laudani
Claudio Laudani
GOGiovanni Occhipinti
Giovanni Occhipinti
MSMarco Spagnolo
Marco Spagnolo
AGAntonio Greco
Antonio Greco
DCDavide Capodanno
Davide Capodanno
BACKGROUND: Results from multiple randomized clinical trials comparing outcomes after intravascular ultrasound (IVUS)– and optical coherence tomography (OCT)–guided percutaneous coronary intervention (PCI) with invasive coronary angiography (ICA)–guided PCI as well as a pivotal trial comparing the 2 intravascular imaging (IVI) techniques have provided mixed results. METHODS: Major electronic databases were searched to identify eligible trials evaluating at least 2 PCI guidance strategies among ICA, IVUS, and OCT. The 2 coprimary outcomes were target lesion revascularization and myocardial infarction. The secondary outcomes included ischemia-driven target lesion revascularization, target vessel myocardial infarction, death, cardiac death, target vessel revascularization, stent thrombosis, and major adverse cardiac events. Frequentist random-effects network meta-analyses were conducted. The results were replicated by Bayesian random-effects models. Pairwise meta-analyses of the direct components, multiple sensitivity analyses, and pairwise meta-analyses IVI versus ICA were supplemented. RESULTS: The results from 24 randomized trials (15 489 patients: IVUS versus ICA, 46.4%, 7189 patients; OCT versus ICA, 32.1%, 4976 patients; OCT versus IVUS, 21.4%, 3324 patients) were included in the network meta-analyses. IVUS was associated with reduced target lesion revascularization compared with ICA (odds ratio [OR], 0.69 [95% CI, 0.54–0.87]), whereas no significant differences were observed between OCT and ICA (OR, 0.83 [95% CI, 0.63–1.09]) and OCT and IVUS (OR, 1.21 [95% CI, 0.88–1.66]). Myocardial infarction did not significantly differ between guidance strategies (IVUS versus ICA: OR, 0.91 [95% CI, 0.70–1.19]; OCT versus ICA: OR, 0.87 [95% CI, 0.68–1.11]; OCT versus IVUS: OR, 0.96 [95% CI, 0.69–1.33]). These results were consistent with the secondary outcomes of ischemia-driven target lesion revascularization, target vessel myocardial infarction, and target vessel revascularization, and sensitivity analyses generally did not reveal inconsistency. OCT was associated with a significant reduction of stent thrombosis compared with ICA (OR, 0.49 [95% CI, 0.26–0.92]) but only in the frequentist analysis. Similarly, the results in terms of survival between IVUS or OCT and ICA were uncertain across analyses. A total of 25 randomized trials (17 128 patients) were included in the pairwise meta-analyses IVI versus ICA where IVI guidance was associated with reduced target lesion revascularization, cardiac death, and stent thrombosis. CONCLUSIONS: IVI-guided PCI was associated with a reduction in ischemia-driven target lesion revascularization compared with ICA-guided PCI, with the difference most evident for IVUS. In contrast, no significant differences in myocardial infarction were observed between guidance strategies.

11 February 2025 in Circulation
Verified
Journal Article
Closed access
AGAntonio Greco
Antonio Greco
SFSimone Finocchiaro
Simone Finocchiaro
MSMarco Spagnolo
Marco Spagnolo
DFDenise Cristiana Faro
Denise Cristiana Faro
MMMaria Sara Mauro
Maria Sara Mauro
DCDavide Capodanno
Davide Capodanno
Atherosclerotic cardiovascular disease is a major health concern worldwide and requires effective preventive measures. Lp(a) (lipoprotein [a]) has recently garnered attention as an independent risk factor for astherosclerotic cardiovascular disease, with proinflammatory and prothrombotic mechanisms contributing to its atherogenicity. On an equimolar basis, Lp(a) is ~5 to 6 times more atherogenic than particles that have been widely associated with adverse cardiovascular outcomes, such as LDL (low-density lipoprotein). Lp(a) can enter the vessel wall, leading to the accumulation of oxidized phospholipids in the arterial intima, which are crucial for initiating plaque inflammation and triggering vascular disease progression. In addition, Lp(a) may cause atherothrombosis through interactions between apoA (apolipoprotein A) and the platelet PAR-1 (protease-activated receptor 1) receptor, as well as competitive inhibition of plasminogen. Because Lp(a) is mostly determined on genetic bases, a 1-time assessment in a lifetime can suffice to identify patients with elevated levels. Mendelian randomization studies and post hoc analyses of randomized trials of LDL cholesterol–lowering drugs showed a causal link between Lp(a) concentrations and cardiovascular outcomes, with therapeutic reduction of Lp(a) expected to contribute to estimated cardiovascular risk mitigation. Many Lp(a)-lowering drugs, including monoclonal antibodies, small interfering ribonucleic acids, antisense oligonucleotides, small molecules, and gene editing compounds, are at different stages of clinical investigation and show promise for clinical use. In particular, increased Lp(a) testing and treatment are expected to have a substantial impact at the population level, enabling the identification of high-risk individuals and the subsequent prevention of a large number of cardiovascular events. Ongoing phase 3 trials will further elucidate the cardiovascular benefits of Lp(a) reduction over the long term, offering potential avenues for targeted interventions and improved cardiovascular outcomes.


15 July 2026
Verified
Book Chapter
Closed access
AGAntonio Greco
Antonio Greco
CRCarmelo Raffo
Carmelo Raffo
DCDavide Capodanno
Davide Capodanno

19 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CRCarmelo Raffo
Carmelo Raffo
DGDaniele Giacoppo
Daniele Giacoppo
DCDavide Capodanno
Davide Capodanno
AGAntonio Greco
Antonio Greco
Antithrombotic therapy management in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) remains challenging as it requires simultaneous protection from cardioembolism and coronary ischemic events while minimizing bleeding. The coexistence of these competing risks, along with their different temporal profiles, has driven a major shift in therapeutic strategies over the past decade. Randomized trials have consistently shown that direct oral anticoagulant (DOAC)-based dual antithrombotic therapy (DAT) reduces bleeding as compared with prolonged triple antithrombotic therapy (TAT), supporting early aspirin withdrawal in most patients. At the same time, pooled analyses suggest that this simplification may be accompanied by a small increase in ischemic risk, particularly during the first month after PCI, when the hazard of stent thrombosis is the highest. Contemporary guideline recommendations from Europe and North America are now broadly aligned in favoring a short periprocedural course of TAT followed by DAT with a DOAC and clopidogrel, then transitioning to oral anticoagulant monotherapy. However, important uncertainty remains for patients with very high ischemic or bleeding risk, including those with acute coronary syndromes, complex PCI, prior stent thrombosis, frailty, chronic kidney disease, previous bleeding, or active cancer. In these settings, treatment decisions cannot rely solely on trial-derived estimates or isolated risk scores, but require individualized, dynamic, and phase-specific assessments. This review critically appraises the biologic rationale, randomized evidence, and contemporary guideline recommendations for antithrombotic therapy in patients with AF undergoing PCI, focusing on areas not fully resolved by current guidelines, including modulation strategies, high-risk and underrepresented populations, tailored antithrombotic management, and emerging therapeutic directions.

29 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CCChiara Cosentino
Chiara Cosentino
LCLuigi Cutore
Luigi Cutore
CRCarmelo Raffo
Carmelo Raffo
CLClaudio Laudani
Claudio Laudani
CCCarmelo Cusmano
Carmelo Cusmano
AGAntonio Greco
Antonio Greco
Historically, beta-blockers have long represented a cornerstone of secondary prevention after acute myocardial infarction (AMI). However, the transition to the modern era of early reperfusion and potent pharmacotherapy has questioned their universal efficacy, particularly in patients without post-AMI left ventricular dysfunction. This review critically analyzes current evidence on the role, timing, and optimal duration of beta-blocker therapy after AMI, with a focus on the impact of left ventricular ejection fraction (LVEF). Relevant literature was identified through searches of PubMed and Web of Science, with particular emphasis on randomized trials and meta-analyses investigating beta-blocker efficacy and safety post-AMI. The search strategy focused on the interaction between LVEF categories and clinical outcomes. Data from historical cohorts and modern trials were synthesized to evaluate the optimal timing and duration of therapy according to the LVEF phenotype. While the survival benefit of beta-blockers remains undisputed for patients with LVEF < 40%, contemporary evidence demonstrates a lack of prognostic advantage for routine beta-blockade in patients with preserved LVEF (i.e., ≥50%). Crucially, recent meta-analyses reveal that patients with LVEF (40–49%) may derive significant benefit from long-term therapy with beta-blockers. Regarding duration, evidence on deprescription remains conflicting. Although earlier data highlighted risks of hemodynamic rebound upon withdrawal, recent trials demonstrate that discontinuing beta-blocker therapy in the chronic phase of AMI may be a safe strategy. Long-term beta-blocker therapy after AMI is supported by robust evidence in patients with LVEF < 40%, whereas emerging but less definitive evidence suggests a potential benefit in those with LVEF 40–49%. Conversely, contemporary randomized trials do not support routine beta-blockade for patients with preserved LVEF (≥50%) in the absence of other clinical indications. As such, further studies are needed to refine patient selection and inform future guideline recommendations across the whole LVEF spectrum.